Literature DB >> 6209227

Carbohydrates as antigenic determinants of tumor-associated antigens recognized by monoclonal anti-tumor antibodies produced in a syngeneic system.

M Ito, E Suzuki, M Naiki, F Sendo, S Arai.   

Abstract

Two monoclonal antibodies (KH-1 and KH-2) against a transplanted fibrosarcoma (KMT-17) in WKA rats were produced by fusing a mouse myeloma (P3-X63-Ag8.653) with spleen cells from syngeneic rats hyperimmunized with KMT-17. Both antibodies showed complement-dependent cytotoxicity against KMT-17. By absorption of cytotoxicity, KH-1 reacted with homologous tumor, other syngeneic fibrosarcomas (KMT-80 and KMT-75), and lung and kidney from normal rats. However, KH-2 reacted with many kinds of tumors and various normal tissues. Antigen specificity was tested by complement fixation and/or solid-phase radioimmunoassay using glycolipids isolated from KMT-17 cells and authentic glycolipids. KH-1 reacted with globotriglycosyl ceramide which was not detected on KMT-17 cells and in cross-reacted weakly with IV3-alpha-galactosyl-lactoneotetraglycosyl ceramide, one of the major glycolipids of KMT-17. The immune reaction was inhibited by alpha-methyl-galactose. KH-2 reacted with lactosyl ceramide and lactoneotetraglycosyl ceramide. The reaction was more potently inhibited by lactose than by beta-methyl-galactose. Antibodies with similar specificity to either KH-1 or KH-2 were elevated in syngeneic rat sera after serial immunization with viable KMT-17 cells.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6209227     DOI: 10.1002/ijc.2910340517

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  A monoclonal antibody for terminal beta-galactose. Use in analysis of glycosphingolipids.

Authors:  A Kalisiak; E Oosterwijk; J G Minniti; L J Old; D A Scheinberg
Journal:  Glycoconj J       Date:  1991-02       Impact factor: 2.916

2.  The expression and distribution of α-Gal gene in various species ocular surface tissue.

Authors:  Yi Shao; Yao Yu; Chong-Gang Pei; Yangluowa Qu; Gui-Ping Gao; Ji-Lin Yang; Qiong Zhou; Lu Yang; Qiu-Ping Liu
Journal:  Int J Ophthalmol       Date:  2012-10-18       Impact factor: 1.779

3.  Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora.

Authors:  U Galili; R E Mandrell; R M Hamadeh; S B Shohet; J M Griffiss
Journal:  Infect Immun       Date:  1988-07       Impact factor: 3.441

4.  Varied presentation of the Thomsen-Friedenreich disaccharide tumor-associated carbohydrate antigen on gold nanoparticles.

Authors:  Andreas Sundgren; Joseph J Barchi
Journal:  Carbohydr Res       Date:  2008-05-08       Impact factor: 2.104

Review 5.  The Galalpha1,3Galbeta1,4GlcNAc-R (alpha-Gal) epitope: a carbohydrate of unique evolution and clinical relevance.

Authors:  Bruce A Macher; Uri Galili
Journal:  Biochim Biophys Acta       Date:  2007-11-22

6.  Evolutionary relationship between the natural anti-Gal antibody and the Gal alpha 1----3Gal epitope in primates.

Authors:  U Galili; M R Clark; S B Shohet; J Buehler; B A Macher
Journal:  Proc Natl Acad Sci U S A       Date:  1987-03       Impact factor: 11.205

7.  Rat serum antibodies binding to high-molecular-weight glycoprotein(s) on syngeneic colon carcinomas, demonstrated by competition with rat monoclonal antibody.

Authors:  B Jansson; T Brodin; H O Sjögren
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 8.  Shiga toxin and its use in targeted cancer therapy and imaging.

Authors:  Nikolai Engedal; Tore Skotland; Maria L Torgersen; Kirsten Sandvig
Journal:  Microb Biotechnol       Date:  2011-01       Impact factor: 5.813

9.  Novel lectin-based chimeric antigen receptors target Gb3-positive tumour cells.

Authors:  Ana Valeria Meléndez; Rubí M-H Velasco Cárdenas; Simon Lagies; Juliane Strietz; Lina Siukstaite; Oliver S Thomas; Jana Tomisch; Wilfried Weber; Bernd Kammerer; Winfried Römer; Susana Minguet
Journal:  Cell Mol Life Sci       Date:  2022-09-12       Impact factor: 9.207

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.